Early Lymphoma Detection: Diagnostic Tests and Their Roles
Lymphoma diagnosis requires a combination of clinical assessment, laboratory tests, imaging, and tissue biopsy. No single test confirms lymphoma; the workup is stepwise.
1. Complete Blood Count (CBC) with Differential
- May show lymphocytosis, anemia, thrombocytopenia, or leukoerythroblastic picture.
- Not diagnostic; nonspecific.
2. Comprehensive Metabolic Panel (CMP) & LDH
- LDH: Elevated in aggressive lymphomas (tumor burden, cell turnover); prognostic marker (IPI score).
- Liver/kidney function, electrolytes, calcium, uric acid (tumor lysis risk).
3. Inflammatory Markers
- ESR, CRP – nonspecific elevation; may correlate with B symptoms.
4. Serologic/Virologic Testing
- HIV, HTLV-1, HBV, HCV, EBV – associated with specific lymphoma subtypes; guide therapy.
5. Imaging
- CT neck/chest/abdomen/pelvis (with contrast): Standard for staging (Ann Arbor), assessing nodal/extranodal involvement, organomegaly.
- PET-CT (FDG): Gold standard for staging FDG-avid lymphomas (DLBCL, HL); assesses metabolic activity, guides biopsy site, monitors response (Deauville score).
- MRI: CNS involvement, spinal cord compression.
- Ultrasound: Initial nodal assessment, guided biopsy.
6. Tissue Biopsy (Definitive Diagnosis)
- Excisional lymph node biopsy – preferred; preserves architecture for histology, immunophenotyping (IHC), flow cytometry, FISH, molecular studies.
- Core needle biopsy – if excision not feasible; must be adequate for subtyping.
- FNA alone is insufficient for primary diagnosis (loss of architecture).
7. Bone Marrow Biopsy & Aspiration
- Staging for many NHL subtypes (e.g., follicular, mantle cell, SLL/CLL).
- Not always needed for early-stage HL or if PET-CT negative.
8. Lumbar Puncture
- If CNS symptoms, high-risk subtypes (Burkitt, lymphoblastic, DLBCL with testis/breast involvement), or PET-CT suggestive.
9. Molecular & Genetic Profiling
- FISH for translocations (t(14;18) BCL2, t(11;14) CCND1, t(8;14) MYC).
- Next-generation sequencing panels for prognosis/targeted therapy.
Workflow Summary
Clinical suspicion → CBC, LDH, CT/PET-CT → Excisional biopsy → IHC/flow/molecular → Subtype classification (WHO) → Staging (Ann Arbor/Lugano) → Risk stratification (IPI, FLIPI, MIPI) → Treatment planning.
Early referral to hematology/oncology optimizes diagnostic accuracy and timely therapy.
Lymphoma - Related Articles
- Cavernous Hemangioma: Benign Vascular Lesion—Monitoring and Treatment Indications
- Understanding Stage 2 Lymphoma: Diagnosis and Treatment
- Thoracic Duct: The Lymphatic System's Return to Circulation
- Mantle Cell Lymphoma & Vietnam Service: No Established Link to Agent Orange
- B-Cell Lymphoma Treatment Delay: Factors and Considerations
- Mesenteric Lymphoma: Symptoms, Diagnosis & What to Expect
- Understanding Hodgkin's Lymphoma in Children: Symptoms & Treatment
